VANCOUVER, BRITISH COLUMBIA - Helix BioPharma Corp. (TSX: HBP, OTC PINK: HBPCD, FRANKFURT: HBP0), a clinical-stage oncology company developing novel therapies for difficult-to-treat cancers, has announced immediate changes to its Board of Directors. Janusz Grabski has resigned from the board, and concurrently, Thomas Mehrling, M.D., Ph.D., the company's Chief Executive Officer, has been formally appointed as a director. This appointment is pursuant to the board nomination right granted to Laevoroc Immunology AG in connection with Helix's 2025 acquisition of substantially all of the assets of Laevoroc Immunology AG and Laevoroc Chemotherapy AG.
These changes are intended to ensure that the board continues to meet Helix's evolving governance and capital markets requirements and has the composition and experience needed to support the company's clinical development and broader corporate objectives. The board expressed gratitude to Mr. Grabski for his service and contributions, wishing him success in future endeavors.
Helix BioPharma is a clinical-stage oncology company focused on developing therapies for underserved patient populations with difficult-to-treat cancers. Its pipeline is led by L-DOS47, a clinical-stage antibody-enzyme conjugate being developed as a combination therapy for non-small cell lung cancer (NSCLC). Additional pipeline candidates include LEUMUNA™, a pre-IND oral immune checkpoint modulator for post-transplant leukemia relapse, and GEMCEDA™, a pre-IND gemcitabine prodrug for advanced solid tumors.
The strategic acquisition from the Laevoroc Group, which brought LEUMUNA and GEMCEDA into Helix's portfolio, was a pivotal move for the company. This acquisition, completed in 2025, expanded Helix's pipeline beyond its lead candidate L-DOS47, positioning the company to address a broader range of cancers. The addition of these pre-IND candidates underscores Helix's commitment to developing innovative therapies for difficult-to-treat cancers.
The board changes come at a crucial time as Helix advances its clinical programs and seeks to strengthen its position in the oncology space. By appointing Dr. Mehrling, who has been leading the company's strategic direction, the board ensures alignment between management and governance. Dr. Mehrling's dual role as CEO and director is expected to facilitate more efficient decision-making and better reflect the company's operational needs.
Investors and stakeholders will likely view these changes as a positive step towards stabilizing leadership and focusing on execution. The board's composition is now tailored to support Helix's growth trajectory, particularly as it prepares for potential milestones in its clinical trials and regulatory interactions.
Helix BioPharma's common shares are listed on the Toronto Stock Exchange (TSX: HBP), quoted on the OTC Pink Market (HBPCD), and listed on the Frankfurt Stock Exchange (FWB: HBP0). For more information, visit Helix BioPharma.
